Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine. The results of the murine study indicate that radionuclide therapy promotes prostate cancer immunogenicity, provoking a cellular response that makes the tumors more receptive to immunotherapy. Prostate cancer is generally viewed as an immunological cold cancer in which immunotherapies only have moderate success. Increasing prostate cancer immunogenicity with prostate-specific membrane antigen (PSMA) radionuclide therapy, however, might render immunotherapies more successful. In our research we sought to exploit this effect by combining radionuclide therapy with immunotherapy in a mouse model of prostate cancer."